BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
X-WR-CALNAME:CTL@WCM Special Panel: Leveraging Alternatives to Animal Model
 s to Transform Drug Development
X-WR-TIMEZONE:Eastern Time (US & Canada)
BEGIN:VEVENT
DTSTAMP:20260520T195718Z
UID:tag:localist.com\,2008:EventInstance_46393506886586
DTSTART:20240530T160000Z
DTEND:20240530T170000Z
DESCRIPTION:A new generation of human model systems are coming to the foref
 ront of drug development\, including novel organoid\, microphysiological a
 nd in silico platforms. With the passage of the FDA Modernization Act 2.0 
 in 2022\, these cutting-edge systems are poised to gain increasing scienti
 fic\, commercial and regulatory acceptance in replacing data traditionally
  sought from animal models. But how far can these systems go in displacing
  animals\, and what commercial and regulatory challenges stand in their pa
 th?\n\nJoin us as we convene a panel of experts in alternative human model
  systems to discuss their changing role in science and business. \n\nPanel
 ists:\n•    Lowry Curley\, Ph.D.\, Co-Founder and CEO of Axosim\n•    
 Krista Durney\, Ph.D.\, Associate Director\, Innovation & Business Develop
 ment at Valo Health\n•    Kristin Bircsak\, Ph.D.\, Principal Scientist 
 at MIMETAS\n•    Iris Bica\, Business Development & Licensing Associate 
 at Weill Cornell Medicine (Moderator)
LOCATION:
SUMMARY:CTL@WCM Special Panel: Leveraging Alternatives to Animal Models to 
 Transform Drug Development
URL;VALUE=URI:https://events.weill.cornell.edu/event/ctlwcm-special-panel-l
 everaging-alternatives-to-animal-models-to-transform-drug-development
END:VEVENT
END:VCALENDAR